View on GitHub

Added entries:

  • (FDA) BRCA1 and BRCA2 somatic and germline variants and sensitivity to olaparib in combination with abiraterone and prednisone or prednisolone for patients with metastatic castration-resistant prostate cancer.
  • (FDA) BRCA1 and BRCA2 germline variants and sensitivity to olaparib for patients with metastatic pancreatic adenocarcinoma.
  • (FDA) BRCA1 and BRCA2 germline variants and sensitivity to olaparib for the treatment of adult patients with HER2-negative high risk early breast cancer.
  • (FDA) ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, and RAD51C somatic variants and sensitivity to talazoparib in combination with enzalutamide for patients with metastatic castration-resistant prostate cancer.

Revised entries:

  • (FDA) BRCA1 and BRCA2 germline variants and sensitivity to olaparib in breast cancer. Revised description to add additional approval details from FDA drug label.